These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 30843188)

  • 1. FGF2 induces breast cancer growth through ligand-independent activation and recruitment of ERα and PRBΔ4 isoform to MYC regulatory sequences.
    Giulianelli S; Riggio M; Guillardoy T; Pérez Piñero C; Gorostiaga MA; Sequeira G; Pataccini G; Abascal MF; Toledo MF; Jacobsen BM; Guerreiro AC; Barros A; Novaro V; Monteiro FL; Amado F; Gass H; Abba M; Helguero LA; Lanari C
    Int J Cancer; 2019 Oct; 145(7):1874-1888. PubMed ID: 30843188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters.
    Giulianelli S; Vaqué JP; Soldati R; Wargon V; Vanzulli SI; Martins R; Zeitlin E; Molinolo AA; Helguero LA; Lamb CA; Gutkind JS; Lanari C
    Cancer Res; 2012 May; 72(9):2416-27. PubMed ID: 22396492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progesterone receptor B recruits a repressor complex to a half-PRE site of the estrogen receptor alpha gene promoter.
    De Amicis F; Zupo S; Panno ML; Malivindi R; Giordano F; Barone I; Mauro L; Fuqua SA; Andò S
    Mol Endocrinol; 2009 Apr; 23(4):454-65. PubMed ID: 19147702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ERαY537S and ERαD538G mutations.
    Yu L; Wang L; Mao C; Duraki D; Kim JE; Huang R; Helferich WG; Nelson ER; Park BH; Shapiro DJ
    Cancer Lett; 2019 Feb; 442():373-382. PubMed ID: 30419347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of an estrogen receptor-regulated gene by first generation progestins requires both the progesterone receptor and estrogen receptor alpha.
    Perkins MS; Louw-du Toit R; Jackson H; Simons M; Africander D
    Front Endocrinol (Lausanne); 2022; 13():959396. PubMed ID: 36187129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kruppel-like factor 9 is a negative regulator of ligand-dependent estrogen receptor alpha signaling in Ishikawa endometrial adenocarcinoma cells.
    Velarde MC; Zeng Z; McQuown JR; Simmen FA; Simmen RC
    Mol Endocrinol; 2007 Dec; 21(12):2988-3001. PubMed ID: 17717078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progesterone induces progesterone receptor gene (PGR) expression via rapid activation of protein kinase pathways required for cooperative estrogen receptor alpha (ER) and progesterone receptor (PR) genomic action at ER/PR target genes.
    Diep CH; Ahrendt H; Lange CA
    Steroids; 2016 Oct; 114():48-58. PubMed ID: 27641443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor α-dependent transcriptional activation and breast carcinogenesis.
    Peng BL; Li WJ; Ding JC; He YH; Ran T; Xie BL; Wang ZR; Shen HF; Xiao RQ; Gao WW; Ye TY; Gao X; Liu W
    Theranostics; 2020; 10(8):3451-3473. PubMed ID: 32206101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between FGFR-2, STAT5, and progesterone receptors in breast cancer.
    Cerliani JP; Guillardoy T; Giulianelli S; Vaque JP; Gutkind JS; Vanzulli SI; Martins R; Zeitlin E; Lamb CA; Lanari C
    Cancer Res; 2011 May; 71(10):3720-31. PubMed ID: 21464042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.
    Rivas MA; Venturutti L; Huang YW; Schillaci R; Huang TH; Elizalde PV
    Breast Cancer Res; 2012 May; 14(3):R77. PubMed ID: 22583478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progesterone receptor modulates ERα action in breast cancer.
    Mohammed H; Russell IA; Stark R; Rueda OM; Hickey TE; Tarulli GA; Serandour AA; Birrell SN; Bruna A; Saadi A; Menon S; Hadfield J; Pugh M; Raj GV; Brown GD; D'Santos C; Robinson JL; Silva G; Launchbury R; Perou CM; Stingl J; Caldas C; Tilley WD; Carroll JS
    Nature; 2015 Jul; 523(7560):313-7. PubMed ID: 26153859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression.
    Knutson TP; Daniel AR; Fan D; Silverstein KA; Covington KR; Fuqua SA; Lange CA
    Breast Cancer Res; 2012 Jun; 14(3):R95. PubMed ID: 22697792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERα-36 regulates progesterone receptor activity in breast cancer.
    Konan HP; Kassem L; Omarjee S; Surmieliova-Garnès A; Jacquemetton J; Cascales E; Rezza A; Trédan O; Treilleux I; Poulard C; Le Romancer M
    Breast Cancer Res; 2020 May; 22(1):50. PubMed ID: 32429997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor-2, derived from cancer-associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling.
    Suh J; Kim DH; Lee YH; Jang JH; Surh YJ
    Mol Carcinog; 2020 Sep; 59(9):1028-1040. PubMed ID: 32557854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timeless Is a Novel Estrogen Receptor Co-activator Involved in Multiple Signaling Pathways in MCF-7 Cells.
    Magne Nde CB; Casas Gimeno G; Docanto M; Knower KC; Young MJ; Buehn J; Sayed E; Clyne CD
    J Mol Biol; 2018 May; 430(10):1531-1543. PubMed ID: 29555554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progesterone Receptor Signaling Promotes Cancer Associated Fibroblast Mediated Tumorigenicity in ER+ Breast Cancer.
    Diep CH; Spartz A; Truong TH; Dwyer AR; El-Ashry D; Lange CA
    Endocrinology; 2024 Jul; 165(9):. PubMed ID: 39041201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progestins reinitiate cell cycle progression in antiestrogen-arrested breast cancer cells through the B-isoform of progesterone receptor.
    McGowan EM; Russell AJ; Boonyaratanakornkit V; Saunders DN; Lehrbach GM; Sergio CM; Musgrove EA; Edwards DP; Sutherland RL
    Cancer Res; 2007 Sep; 67(18):8942-51. PubMed ID: 17875737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.
    Jin K; Park S; Teo WW; Korangath P; Cho SS; Yoshida T; Győrffy B; Goswami CP; Nakshatri H; Cruz LA; Zhou W; Ji H; Su Y; Ekram M; Wu Z; Zhu T; Polyak K; Sukumar S
    Cancer Discov; 2015 Sep; 5(9):944-59. PubMed ID: 26180042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.